No question about it: Express Scripts, the country's largest pharmacy benefit manager, just took a big hit. Shares are down about 20% since some unmistakably pessimistic language filling a recent earnings release. But is this really a reason to jump ship? In this video, Motley Fool health-care analyst Brenton Flynn outlines a trio of trends that support the bull argument for Express Scripts longer term.
Has Express Scripts' long-term outlook really changed, or is this a classic example of Wall Street' blinded by its own short-term lens? In this brand-new premium report on Express Scripts, Stock Advisor analyst Jim Mueller dives deep into the company's prospects. Here's a hint: There's plenty of room for growth. You'll understand why, along with an outline of the key must-watch areas of the company, if you claim a copy by clicking here now.